Clinical trials for Autosomal dominant multiple pterygium syndrome
13 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGNCT06941012Validation of α-synuclein Modifications in Parkinson's dIsoRder EvolutionCasa di Cura IGEA · PI: Marco Feligioni, PHD
- RECRUITINGNCT06949670Alpha-Synuclein PET/CT in Various α-Syn-Related DiseaseTianjin Medical University
- RECRUITINGPhase 3NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)Merck Sharp & Dohme LLC · PI: Medical Director
- RECRUITINGPhase 2NCT05281003Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)Fudan University · PI: Haiquan Chen, M.D., Ph.D.
- ACTIVE NOT RECRUITINGPhase 1NCT05382325A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)Merck Sharp & Dohme LLC · PI: Medical Director
- RECRUITINGNCT07533799The Swedish BioFINDER Sleep StudySkane University Hospital · PI: Erik Stomrud, MD, PhD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04995523A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCAstraZeneca
- RECRUITINGPHASE1, PHASE2NCT04938817Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)Merck Sharp & Dohme LLC · PI: Medical Director
- RECRUITINGNCT04724941Prodromal Alpha-Synuclein Screening in Parkinson's Disease StudyUniversity Hospital Schleswig-Holstein · PI: Daniela Berg, Prof.Dr.
- ACTIVE NOT RECRUITINGPhase 3NCT04624204Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)Merck Sharp & Dohme LLC · PI: Medical Director, MD
- RECRUITINGNCT07535385RADIOLOGICAL AND CLINICAL EVALUATION OF RENAL EMBOLIZATION USING EVOH IN DIALYSIS PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A PROSPECTIVE LONGITUDINAL OBSERVATIONAL STUDYFondazione IRCCS Policlinico San Matteo di Pavia
- ACTIVE NOT RECRUITINGPhase 3NCT03553836Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)Merck Sharp & Dohme LLC · PI: Medical Director
- ACTIVE NOT RECRUITINGPhase 2NCT03383094Chemoradiation vs Immunotherapy and Radiation for Head and Neck CancerLoren Mell, MD · PI: Loren Mell, MD